Barclays Cuts Owens & Minor (NYSE:OMI) Price Target to $14.00

Owens & Minor (NYSE:OMI) had its target price decreased by Barclays from $18.00 to $14.00 in a research report released on Tuesday,Benzinga reports. Barclays currently has an equal weight rating on the stock.

OMI has been the topic of a number of other reports. Robert W. Baird cut their price target on shares of Owens & Minor from $19.00 to $14.00 and set a “neutral” rating on the stock in a research note on Tuesday. Citigroup upgraded Owens & Minor from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $24.00 to $19.00 in a research note on Friday, July 19th. JPMorgan Chase & Co. decreased their price objective on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating for the company in a research note on Wednesday, August 21st. Finally, StockNews.com lowered shares of Owens & Minor from a “buy” rating to a “hold” rating in a research report on Monday, August 26th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $18.50.

Owens & Minor Trading Down 1.8 %

OMI traded down $0.23 during trading hours on Tuesday, reaching $12.53. The company’s stock had a trading volume of 25,801 shares, compared to its average volume of 834,575. The stock has a market cap of $966.01 million, a PE ratio of -19.63, a P/E/G ratio of 0.39 and a beta of 0.41. Owens & Minor has a fifty-two week low of $11.42 and a fifty-two week high of $28.35. The business’s 50-day moving average is $14.35 and its 200-day moving average is $16.06. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.09 and a quick ratio of 0.51.

Owens & Minor (NYSE:OMI) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.68 billion. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.44 EPS. As a group, equities research analysts predict that Owens & Minor will post 1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. ProShare Advisors LLC raised its holdings in Owens & Minor by 7.4% in the first quarter. ProShare Advisors LLC now owns 15,021 shares of the company’s stock valued at $416,000 after buying an additional 1,029 shares during the period. Texas Permanent School Fund Corp raised its stake in shares of Owens & Minor by 1.8% in the 1st quarter. Texas Permanent School Fund Corp now owns 66,953 shares of the company’s stock valued at $1,855,000 after acquiring an additional 1,156 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in shares of Owens & Minor by 76.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,126 shares of the company’s stock valued at $43,000 after acquiring an additional 1,356 shares in the last quarter. Arizona State Retirement System boosted its position in Owens & Minor by 7.7% during the 2nd quarter. Arizona State Retirement System now owns 20,371 shares of the company’s stock worth $275,000 after purchasing an additional 1,449 shares during the period. Finally, Quarry LP increased its holdings in Owens & Minor by 290.1% in the 2nd quarter. Quarry LP now owns 2,099 shares of the company’s stock valued at $28,000 after purchasing an additional 1,561 shares in the last quarter. 98.04% of the stock is currently owned by hedge funds and other institutional investors.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.